KOL Insight - Atopic Dermatitis

This report provides an in-depth qualitative analysis of the evolving treatment landscape for moderate-to-severe atopic dermatitis, based on interviews with leading dermatology KOLs across the US and Europe. It examines expert perceptions of newly launched and pipeline therapies, with particular attention to the rise in Ebglyss, mixed views on Nemluvio, and how amlitelimab is positioned relative to other emerging agents. Gain expert insights on current prescribing trends, key clinical considerations, and how the market may shift as new data become available.

Key Questions Answered:

• 1. How is Dupixent currently used in atopic dermatitis, and how might its prescribing change in the future?
• 2. Which recently launched therapies and mechanisms of action are most promising for atopic dermatitis?
• 3. Which pipeline products are expected to impact the atopic dermatitis treatment landscape?
• 4. What are the key clinical trials influencing current and future prescribing trends?
• 5. How do experts view the efficacy and safety of new and emerging therapies compared to established treatments?
• 6. What factors are driving or limiting the uptake of new atopic dermatitis therapies?
• 7. How do KOLs expect the treatment algorithm for moderate-to-severe atopic dermatitis to evolve?
• 8. What are the main unmet needs in the management of moderate-to-severe atopic dermatitis?
• 9. How do patient characteristics and disease severity influence systemic therapy selection?
• 10. What is the anticipated impact of new therapies on current market leaders in atopic dermatitis?

Key Brands:

Partial List of Participating Experts:

• Professor of Dermatology at the University of California San Francisco, San Francisco, CA.
• Professor of Dermatology, Pathology, and Public Health Sciences at Wake Forest University School of Medicine, Winston-Salem, NC.
• Clinical Professor of Dermatology at the University of Louisville School of Medicine, Louisville, KY.
• Professor of Dermatology at the University of Verona, Verona, Italy.
• Professor of Dermatology at Paul Sabatier University, Toulouse, France.
• Professor of Dermatology and Consultant Dermatologist at Salford Royal NHS Foundation Trust; and Director of the Dermatopharmacology Unit at the University of Manchester, Manchester, UK.

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.